4倍,差异有统计学意义(P<0 01);NCI-H446细胞对RGDLP-PTX的摄取效率是LPPTX的3 8倍,差异有统计学意义

4倍,差异有统计学意义(P<0.01);NCI-H446细胞对RGDLP-PTX的摄取效率是LPPTX的3.8倍,差异有统计学意义(P<0.01);RGDLP-PTX对A549细胞和NCI-H446细胞的增殖抑制率具有浓度依赖性;在相同紫杉醇浓度下,RGDLP-PTX对A549细胞和NCI-H446细胞的增殖抑制率显著强于LP-PTX和游离紫杉醇,差异有统计学意义(P<0.01);RGDLP-PTX,LP-PTX和游离紫杉醇诱导肺癌A549细胞的凋亡率分别为48.3%,27.4%和35.5%,与生理盐水组比较,差异有统计学意义(P<0.01);NCI-H446细胞凋亡率分别为41.3%,22.8%和34.1%,与生理盐水组比较,差异有统计学意义(P<0.01)。RGDLP-PTX,LP-PTX和游离紫杉醇对肺癌肿瘤的抑制率分别为69.3%,47.5%和24.4%,差异有统计学意义(P<0.01)。结论:RGD修饰载紫杉醇脂质体能够高效抑制肺癌细胞的增殖和肿瘤的生长,是一种有效的肺癌靶向给药系统。
程序性细胞死亡因子1(PD-1)是由PDCD-1基因编码的一种表达在T细胞细胞膜和细胞质中的抑制性受体。PD-1及其配体PD-L1(B7-H1/CD274)、PD-L2(B7-DC/CD273)在调节免疫反应和维持外周免疫耐受中具有重要作用。PD-1/PD-L1通过抑制T淋巴细胞增殖、存活和效应功能诱导抗原特异性T细胞凋亡,促进CD4+T细胞向Foxp3+调节性T细胞分化从而促进肿瘤的发生发展。抗PD-1单克隆抗体(BMS-936558等)及抗PD-L1单克隆抗体(BMS-936559等)的安全性及临床疗效的研究为非小细胞肺癌的治疗带来了新突破,免疫靶向治疗将会成为其治疗的新方向。
The

而且 incidence of gastric cancer(GC) fell dramatically over the last 50 years, but according to IARC-Globocan 2008, it is the third most frequent cause of cancerrelated deaths with a case fatality GC ratio higher than other common malignancies. Surgical resection is the primary curative treatment for GC though the overall 5-year survival rate remains poor(approximately 20%-25%). To improve the outcome of resectable gastric cancer,

different treatment strategies have been evaluated

such as adjuvant or perioperative chemotherapy. In resected Raf抑制剂 gastric cancer, the A-1210477 花费 addition of radiotherapy to chemotherapy does not appear to provide any additional benefit. Moreover, in metastatic patients, chemotherapy is the mainstay of palliative therapy with a median overall survival of 8-10 mo and objective response rates of merely 20%-40%. Therefore, the potential for making key beneficial progress is to investigate the GC molecular biology to realize innovative therapeutic strategies, such as specific immunotherapy. In this review, we provide a panoramic view of the different immune-based strategies used for gastric cancer treatment and the results obtained in the most significant clinical trials. In detail, firstly we describe the therapeutic approaches that utilize the monoclonal antibodies while in the second part we analyze the cell-based immunotherapies.
目的探讨免疫组化(immunohistochemistry,IHC)在检测非小细胞肺癌(non-small cell lung cancer,NSCLC)中间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合基因表达异常的准确性,并观察ALK阳性患者的临床病理特征。方法收集NSCLC患者石蜡标本234例,使用兔单克隆D5F3抗体行ALK蛋白IHC检测,对其中ALK阳性标本采用反转录聚合酶链反应(reverse transcription-polymerase chain reaction,RT-PCR)检测验证。结果 234例NSCLC中,IHC检测ALK融合基因蛋白阳性率为8.97%(21/234),经RT-PCR检测验证有14例存在ALK基因融合,阳性率为5.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>